The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...
If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.
Bristol Myers Squibb Canada (BMS) is pleased to announce that OPDIVO® SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements. Quebec is the first ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many ...
Celltrion to seek approval for Herzuma subcutaneous injection in first half of next year celltrion to offer cmo services converting iv drugs to rapid five‑minute sc injections ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback